Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of VX-407 in adults with ADPKD and a subset of PKD1 variants
NL-OMON59456Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of VX-407 in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Vertex Pharmaceuticals. Primary endpoint: Proportion of subjects with percent change from baseline in htTKV less than or equal to 0 on MRI over time. Started Apr 2026; status: completed.
02
Drugs
VX-407
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NL-OMON59456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59456.